Neuromuscular Disorders 3

185
WFN15-0361
Neuromuscular Disorders 3
Salbutamol benefits children with congenital myasthenic syndrome due to ALG2 mutation
M. Salih1, M.Z. Seidahmed2, H.Y. El Khashab3, D. Hicks4, G.T. Farsani5, S. Laval5, J. Müller5, H. Lochmüller5, 6Pediatrics, King Saud University, Riyadh, Saudi Arabia; 6Institute of Genetic Medicine, Newcastle University, Newcastle, United Kingdom

Background: We previously reported on four siblings who had congenital myasthenic syndrome (CMS) due to ALG2 mutation. Three of them showed slowly progressive deterioration and were wheelchair bound. Another patient, reported by others, with CMS due to ALG2 mutation responded to pyridostigmine therapy.

Objective: To report on the beneficial effect of salbutamol in 4 patients with CMS due to ALG2 mutation who did not respond to pyridostigmine therapy.

Patients and methods: Four siblings (one male and 3 females, age range 4.1-25.4 years) belonging to a multiplex, consanguineous Saudi family featuring CMS due to ALG2 mutation received oral salbutamol (4 mg three times daily). Previous trial of pyridostigmine therapy was not effective. The response was assessed by QMG score at baseline and 1–3 months.

Results: An increasingly positive response, as measured by the QMG score, was noted after only one month of salbutamol, which was well tolerated in all patients. Improvement in specific subcomponents of the QMG score such as leg outstretched in 45° supine, and raising arm 90° was most marked. The youngest child could stand with support after the third month of therapy.

Conclusion: Salbutamol is an effective treatment in CMS due to ALG2 mutation. This study provides class IV evidence that salbutamol given at a dose 12 mg/day improves function as measured by the QMG score.

doi:10.1016/j.jns.2015.08.262

187
WFN15-0366
Neuromuscular Disorders 3
A case of Becker muscular dystrophy with rimmed vacuoles
N. Khanloua1, S. Mishra2, N. Rafiei3, H. Mohammad khanli4, 5Neurology, David Geffen School of Medicine UCLA, Los Angeles, USA; 5Neurology, Olive View UCLA Medical Center, Los Angeles, USA

Objective: We describe rimmed-vacuoles as principle diagnostic pathology on muscle biopsy of a patient with genetically confirmed Becker muscular dystrophy (BMD).

Background: Rimmed vacuoles can be seen in subsets of muscle disorders such as distal myopathies and hereditary inclusion body myopathy (hIBM). They are not pathognomonic of dystrophinopathy.

Case presentation: 34 year old Persian male presented for evaluation of slowly progressive proximal muscle weakness since the age of 17, bilateral calves hypertrophy, and cardiomyopathy. He had no family history of muscle disorder. CK was 914 IU/L and EMG/NC showed myopathy with mild irritability. Skeletal muscle biopsy showed a chronic myopathy with no active regeneration/regeneration. Salient feature of the biopsy was rimmed vacuoles with confirmed autophagic nature on enzyme histochemistry and electron microscopy. Membrane
protein immunohistochemistry (IHC) did not show any deficiency. In view of strong clinical consideration of BMD genomic sequencing analysis of the DMD gene was performed. This showed deletion of exons 45–47 confirmatory for Becker muscular dystrophy.

**Discussion:** Initial pathologic impression was that of a dystrophic/myopathic syndrome characterized by occasional rimmed vacuoles but without significant inflammation. The clinical phenotype did not suggest a "distal myopathy" but rather a hereditary syndrome with impression of hIBM. Pathologic differentials included variants of limb-girdle muscular dystrophies. A dystrophinopathy was not considered in view of the normal IHC.

**Conclusion:** Our findings broaden the differentials of vacuolar myopathies. In relevant clinical setting a dystrophinopathy should be considered in a biopsy combing vacuolar damage and normal membrane IHC.

doi:10.1016/j.jns.2015.08.263

### 188
**WFN15-0453**
**Neuromuscular Disorders 3**
**Clinical profile and molecular diagnosis of Chinese patients with facioscapulohumeral muscular dystrophy**

N. Wang, Z.Q. Wang, F. Ling. Neurology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China

**Background and objective:** FSHD is a common muscular inherited disorder, caused by contraction of D4Z4 repeats on chromosome 4q35. However, the complicated genotype-phenotype relationship remains a controversial subject.

**Materials and methods:** 178 affected individuals from 136 unrelated Chinese families were investigated. Genetic testing was performed by PFGE separation and southern blotting. A ten-grade FSHD clinical severity scale was adopted.

**Results:** A significantly inversed correlation between short EcoRI fragment size and disease severity was observed in all symptomatic patients (Fig. 1). However, in female group, either the asymptomatic carriers or severe patients showed large variation in the size of short EcoRI fragment (Table). It also showed significant difference between the sporadic and familial cases in the size distribution of short EcoRI fragments ($C^2 = 5.69, P < 0.05$, Fig. 2).

**Conclusion:** A majority of phenotypic spectrum was still incompatible with their heterozygous contraction of D4Z4 repeats, especially in female cases. Our results suggested that there are multi-factors synergistically modulating the phenotype of FSHD.

doi:10.1016/j.jns.2015.08.264

### 189
**WFN15-0455**
**Neuromuscular Disorders 3**
**Favorable response of botulinum toxin to the axial muscle spasms in a patient with stiff-person syndrome autoimmune: A case report**

D. Correa Ospina, P. Paula Andrea Millán Giraldo, J. José Mauricio Cárdenas Prieto, O. Omar Fredy Buriticá, S. Simón Uribe Vargas. Antioquia, Instituto Neurologico de Colombia, Medellín, Colombia

**Summary**

**Introduction:** The stiff-person syndrome is a rare neurological disorder characterized by marked axial stiffness with severe hyperlordosis and painful muscle spasms, which can be triggered by sensory and emotional stimuli. The antibodies against glutamic acid decarboxylase (GAD) suggest an autoimmune etiology. Various treatments (benzodiazepines, baclofen, botulinum toxin, immunoglobulin and immunosuppressive therapy) have been used with varying response.

**Case report:** The case of a female patient of 20 years, with clinical picture of one and a half axial hypertension and left-sided, marked lumbar lordosis and very painful muscle spasms axial paroxysmal is reported; progressive course. Additional tests are performed: oligoclinal bands with pattern 2 and anti-GAD positive serum; occult tumor (total body PET normal) is discarded. Diagnosis of stiff-person syndrome autoimmune done. Management starts with benzodiazepines, baclofen and immunoglobulin for 4 cycles (2 g/
kg every 2 months); without obtaining a sustained clinical response to axial muscle spasms and the lumbar lordosis. It was decided to apply botulinum toxin type A (Dysport) 500 U distributed in lumbar, thoracic and cervical paraspinal musculature; evidencing the fifth day a resolution of muscle spasms and improvement in lumbar lordosis (pre-90° and post-76° angle), achieving improvement in the patient’s pain, posture and obtaining an independent way.

**Conclusion:** The use of botulinum toxin can be a good therapeutic option for the management of pain and muscle spasms that do not respond to other treatments for people with stiff-person syndrome. The use of botulinum toxin is a therapeutic alternative to improve posture of these patients associated with hyperlordosis.

doi:10.1016/j.jns.2015.08.265

**190**

**WFN15-0556**

**Neuromuscular Disorders 3**

**Dysferlinopathies in Uruguay: First four genetically confirmed cases with different phenotypes**

M. Leonardi, H. Hackembruch, J. Higgie, R. Rozada, L. Vernengo, L. Carrasco, J. Marques, L. Repetto, L. Guggeri, A. Perna. *Hospital de Clínicas, Instituto de Neuropatología, Montevideo, Uruguay; Facultad de Medicina, Departamento de Genética, Montevideo, Uruguay; Hospital Maciel, Servicio de Neurología, Montevideo, Uruguay; Laboratorio Genia, Montevideo, Uruguay*

**Background:** Primary dysferlinopathies are a heterogeneous group of muscular dystrophies autosomal recessive caused by mutations in chromosome 2, which encodes the dysferlin protein. The clinical presentation is variable. Hyper-CKemia is very frequent. Affected patients may present with involvement of the posterior compartment of leg in Miyoshi myopathy (MM), proximal involvement in limb girdle muscular dystrophy type 2B (LGMD2B) or less commonly, with involvement of the anterior tibial compartment.

**Objective:** Describe the clinical presentation in the first cases of dysferlinopathies diagnosed in Uruguay.

**Patients:**

**Case 1:** Male, 30 y. At 15 experience difficulty in sports practice, with decreased muscle mass of both calves at the beginning, with progression to proximal muscles. Serum CK: 37,000. With clinical raise of MM, confirmatory genetic study was obtained.

**Case 2:** Male, 35 y. Two years evolution of lower limb fatigue and gait disturbance. Bilateral, predominantly proximal and left amyotrophies with mild paresis in muscle groups of the hip and knee joint with conserved distal forces. Serum CK: 13,000. The genotype was consistent with dysferlinopathy of LGMD2B.

**Case 3:** Female, 32 y. Initially distal leg myopathy at 22 which has progressed to involve the proximal legs, with a slower progression than Case 1. Serum CK: 5000. The analyses of dysferlin gene detected deleterious mutation.

**Case 4:** Female, 69 y. Phenotype of LGMD2B. The analyses of dysferlin gene detected a recently disease-causing mutation.

**Conclusion:** We described the first four cases of dysferlinopathies with molecular confirmed diagnosis in Uruguay: two LGMD2B and two MM.

doi:10.1016/j.jns.2015.08.266

**191**

**WFN15-0601**

**Neuromuscular Disorders 3**

**Familial polyglucosan body myopathy: A clinical spectrum**

C. Angelini, M. Fanin, A. Nascimbene, M. Savarese, V. Nigro. *Neurological Center, IRCCS S. Camillo, Venice, Mestre, Italy; Neurosciences, Neurology, Padova, Italy; Pathology, TIGEM, Naples, Italy*

**Background:** Polyglucosan body myopathies are due to heterogeneous causes.

**Objectives.** Mutations in the newly identified RBCK1 gene have been recognized to be a rare cause of polyglucosan body myopathy. Here we report a novel family in which a form of adult-onset limb-girdle myopathy was associated with polyglucosan storage in muscle.

**Methods and patients:** In 3 affected relatives we investigated the clinical phenotype, the muscle morphological and ultrastructural features, the RBCK1 genotype and the role of ubiquitin–proteasome and lysosomal-autophagic degradation pathways by analysing ubiquitin, p62/SQSTM1, LC3 and MuRF-1 proteins.

**Results:** The phenotype in all 3 patients was characterized by limb-girdle muscular dystrophy with onset in the fifth decade, associated with autoimmune disorders in 2 cases (generalized vitiligo, chronic inflammatory demyelinating polyneuropathy), without overt cardiac impairment. Accumulation of PAS-positive, amylose-resistant polyglucosan bodies was detectable in 2 of the 4 muscle biopsies studied. Immunofluorescence analysis showed that the inclusions were strongly labelled for ubiquitin and p62/SQSTM1, and immunoblotting revealed increased levels of MuRF-1 and LC3-II proteins in muscles from patients as compared to controls.

**Conclusions:** As compared with cases with RBCK1-related myopathy, this family shows late-onset of limb girdle muscular dystrophy and lack of cardiac involvement, whereas muscle histopathological features are completely matching. We offered evidence supporting the role of both the ubiquitin–proteasome and the lysosomal–autophagic degradation pathways in this family, although the mechanism generating polyglucosan bodies in this family is most likely in glycogenin-1 (under investigation).

doi:10.1016/j.jns.2015.08.267
changes of motor, and sensory nerves, with the tendency to small fibre impairment. The clinically obvious polyneuropathy was found only in one patients with anti-MAG antibodies.

**Conclusion:** The presence of the electrophysiological changes of peripheral nerves in the patients with primary brain tumors, and positive antineural antibodies, suggest the autoimmunological response in the peripheral nervous system. We considered the possibility of paraneoplastic neurological syndromes in the presented cases.

doi:10.1016/j.jns.2015.08.268